SLC5A2 and chronic kidney disease: Sodium-glucose cotransporter (SGLT-2) inhibitors that are a relatively newer class of antidiabetic medications have emerged as important therapeutic agents that reduce cardiovascular events, hospitalization from heart failure, as well as the progression of chronic kidney disease (CKD) in both diabetic and non-diabetic populations.